Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
References
EntrestoⓇ
1
IQVIA National Prescription Audit as of Sep '22.
2
Eligible patients defined as prevalent HFrEF patients within each market's label. G7: US, CA, JP, DE, FR, IT, UK/
3
Zhang et al., ESC Heart Failure 2020; 7: 3841
4
Proudfoot et al., Int J Cardiol. 2021; 331:164
5
6
Including, but not limited to, the recent 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (Heidenreich et al., J Am Coll Cardiol. 2022)
Approved indications differ by geography. Examples include "indicated to reduce the risk of cardiovascular death and hospitalization for HF in adult patients with CHF. Benefits are most clearly evident in
patients with LVEF below normal." (US) HFrEF (EU) HFrEF and HTN (China and JP)
7
Novartis estimate of patients on treatment across all indications
95 Investor Relations | Q3 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation